AKTS
Aktis Oncology, Inc. Common stock
NASDAQ: AKTS · HEALTHCARE · BIOTECHNOLOGY
$19.73
-5.13% today
Updated 2026-06-05
Market cap
$1.12B
P/E ratio
—
P/S ratio
135.77x
EPS (TTM)
$-1.21
Dividend yield
—
52W range
$15 – $29
Volume
0.2M
Aktis Oncology, Inc. Common stock (AKTS) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
+36.7%
Last 4 quarters
Revenue YoY growth
-57.0%
Most recent quarter
EPS YoY growth
-171.4%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+11.9%
Last 2 reports
Positive reaction rate
100%
2 of 2 quarters
Largest single-day move
+17.8%
2026-03-30
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-05-11 | $-0.38 | -15.2% | $18.60 | $19.73 | +6.1% |
| 2026-03-30 | $-0.28 | +75.3% | $15.19 | $17.89 | +17.8% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | $-0.33 | $-0.38 | -15.2% | $3.23M | — |
| 2025-12-31 | $-1.15 | $-0.28 | +75.3% | $1.87M | — |
| 2025-09-30 | $0.00 | $-16.06 | — | — | — |
| 2024-09-30 | $-0.08 | $-0.04 | +50.0% | $9.03M | +28.9% |
| 2024-03-31 | $-0.12 | $-0.14 | -16.7% | $7.51M | +2.1% |
| 2023-12-31 | $-0.18 | $-0.19 | -5.6% | $7.02M | +19.6% |
| 2023-09-30 | $-0.18 | $-0.27 | -50.0% | $7.00M | +25.8% |
| 2023-03-31 | $-0.21 | $-0.20 | +4.8% | $7.36M | — |
| 2022-12-31 | $-0.25 | $-0.19 | +24.0% | $5.87M | — |
| 2022-09-30 | $-0.23 | $-0.28 | -21.7% | $5.57M | — |
| 2022-03-31 | $-0.23 | $-0.22 | +4.3% | — | — |
Frequently asked questions
Has Aktis Oncology, Inc. Common stock beaten earnings estimates?
Aktis Oncology, Inc. Common stock has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, averaging a +36.7% surprise over the last 3. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.
How does AKTS stock react to earnings?
AKTS has moved an average of +11.9% the day after earnings over its last 2 reports, finishing higher after 2 of them. Next-day moves show how the market digests results in the short term, and repeated dips on strong reports usually mean expectations were already priced in.
What is Aktis Oncology, Inc. Common stock's revenue growth rate?
Aktis Oncology, Inc. Common stock reported year-over-year revenue growth of -57.0% in its most recent quarter, with EPS up -171.4%. Reading revenue growth alongside margins shows whether that growth is translating into profit.